Article Text

Download PDFPDF
EP804 Prognostic role of second-line platinum-based therapy in recurrent platinum resistant ovarian cancer patients – data from real-world clinical practice in poland
  1. L Bodnar1,
  2. P Knapp2,
  3. J Sznurkowski3,
  4. R Mądry4,
  5. A Gąsowska-Bodnar5,
  6. P Blecharz6,
  7. M Sikorska7,
  8. A Timorek8,
  9. A Ptak-Chmielewska9,
  10. R Jach10,
  11. Polish Group of Oncological Gynaecology
  1. 1Department of Oncology, University of Warmia and Mazury in Olsztyn, Olsztyn
  2. 2Department of Gynecology and Gynecologic Oncology, Medical University of Bialystok, Białystok
  3. 3Department of Oncological Surgery, Medical University of Gdańsk, Gdańsk
  4. 4Clinic of Oncology, Poznan University of Medical Sciences, Poznań
  5. 5Department of Gynecology and Gynecologic Oncology, Military Institute of Medicine, Warsaw
  6. 6Department of Gynecologic Oncology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Kraków
  7. 7Department of Gynecology and Obstetrics, Faculty of Medical Sciences, University of Warmia and Masuria, Olsztyn
  8. 8Department of Obstetrics, Gynecology and Oncology, Warsaw Medical University and Brodnowski Hospital
  9. 9Institute of Statistics and Demography, Warsaw School of Economics, Warsaw
  10. 10Department of Gynecology and Oncology, Jagiellonian University College, Kraków, Poland


Introduction/Background Strategy of treatment in patients with recurrent ovarian cancer (OC) dependents on platinum-free interval (PFI). We aimed to compare survival in ‘platinum resistant’ OC patients who received platinum-based or non-platinum chemotherapy at first relapse in real world practice based.

Methodology Data of OC patients treated with primary debulking surgery and standard chemotherapy (paclitaxel/platinum analogs) between January 1, 2011 and December 31, 2011 were extracted from Polish National Health Fund Database. Further overall survival (OS) was compared between patients who received any type of chemotherapy up to 6 months PFI.

Results 17% (227/1369) patients classified as ‘platinum-resistant’ by the 6-month threshold of PFI and 29% (66/227) of those group, were treated with Pt-based chemotherapy at second line. Median OS after platinum-based 2-nd line chemotherapy was significantly longer compared to non- platinum chemotherapy group (median OS was 28.1 months, 95% CI: 23.3–42.0 vs. 16.4 months, 95% CI: 13.1–21.0; HR=0.71, 95% CI, 0.51–0.99; P=0.049). This effect was seen, among patients with PFI of 3–6 months (median OS was, 28.1 months, 95% CI: 23.1–42.0 vs 14.3 months, 95% CI: 10.4–40.5, respectively; HR=0.61, 95%CI, 0.39–0.96; P=0.0336). but not in PFI <3months group (HR=0.88, 95% CI, 0.52 to 1.49, P=0.6342).

Conclusion Our results from real world data based on nationwide population cohort study shows that six-months PFI as an arbitrary threshold for subsequent Pt-based chemotherapy is questionable. Biomarkers of platinum sensitivity are needed to identify potential responders, especially in group of patients with PFI 3–6 months.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.